Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis by Gurumurthy, Prema et al.
280 • CID 2004:38 (15 January) • BRIEF REPORT
B R I E F R E P O R T
Malabsorption of Rifampin
and Isoniazid in HIV-Infected Patients
With and Without Tuberculosis
Prema Gurumurthy,1 Geetha Ramachandran,1 A. K. Hemanth Kumar,1
S. Rajasekaran,2 C. Padmapriyadarsini,1 Soumya Swaminathan,1
P. Venkatesan,1 L. Sekar,1 S. Kumar,2 O. R. Krishnarajasekhar,2
and P. Paramesh2
1Tuberculosis Research Centre (Indian Council of Medical Research)
and 2Government Hospital for Thoracic Medicine, Tambaram, Chennai, India
The absorption of rifampin, isoniazid, and D-xylose in pa-
tients with human immunodeficiency virus (HIV) infection
and diarrhea, in patients with HIV infection and tuberculosis
(TB), in patients with pulmonary TB alone, and in healthy
subjects was studied. Percentage of dose of the drugs, their
metabolites, and D-xylose excreted in urine were calculated.
A significant reduction in the absorption of drugs and D-
xylose in both the HIV infection/diarrhea and HIV infection/
TB groups was observed ( ), and the correlation be-P ! .05
tween them was significant. Our results indicate that patients
with HIV infection and diarrhea and those with HIV infec-
tion and TB have malabsorption of rifampin and isoniazid.
Although most HIV-infected patients with tuberculosis (TB)
respond well to rifampin-based antimycobacterial drug regi-
mens [1], recent reports suggest that malabsorption of anti-
mycobacterial drugs occurs in selected HIV-infected patients,
particularly those with advanced HIV infection [2–6]. In theory,
the resulting lower drug exposure may contribute to acquired
drug resistance and reduced effectiveness of anti-TB treatment
[7]. The degree of drug malabsorption appears to be more
pronounced in North American populations [6, 8] than in
African populations [9, 10]. Many factors might contribute to
this difference across studies and across populations, including
variations in the type and severity of concurrent gastrointestinal
infection. Although it is not known which specific factor or
combination of factors produce drug malabsorption, it remains
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reasonable to consider this in patients with concurrent TB and
HIV infection.
Information on absorption of anti-TB drugs in HIV-infected
subjects in India is not available. Therefore, an investigation to
study the absorption of rifampin and isoniazid (based on the
urinary excretion of the drugs and their metabolites) in HIV-
infected patients with and without TB was undertaken. The D-
xylose absorption test was also performed to assess the ab-
sorptive capacity of the intestines.
Material and methods. The study was conducted at the
Government Hospital of Thoracic Medicine (Tambaram, Chen-
nai, India). All study participants were men and were admitted
to the hospital for clinical problems. They were required to
meet the following criteria: they were 18–50 years of age; no
significant hepatic or renal dysfunction (i.e., liver enzymes,
blood urea, and serum creatinine levels were within normal
limits) was present; they were not diabetic; they did not have
a coexisting medical illness that might interfere with drug phar-
macokinetics, apart from HIV infection and diarrhea; and they
were willing to provide informed written consent.
The participants consisted of 23 HIV-seronegative patients
with pulmonary TB (group 1); 40 patients with advanced HIV
infection and diarrhea (group 2); 26 patients with HIV infection
and TB, 20 of whom had diarrhea (group 3); and 10 healthy
volunteers (group 4). Participants in group 2 had a history of
recurrent episodes of watery stools (i.e., 6–8 watery stools per
day for 10 consecutive days in 1 month) at the start of the
study. Examination of stool specimens for detection of oppor-
tunistic enteric pathogens was performed for all patients with
diarrhea. Stool specimens were stained with a modified acid-
fast bacillus stain but were not cultured for mycobacteria. Pul-
monary TB was diagnosed on the basis of bacteriological in-
vestigations (sputum smear and culture for mycobacteria),
which were supported by clinical and radiological features. Di-
agnosis of HIV infection was based on 3 positive results of tests
(2 rapid tests [Tridot {Mitra and Co.} and Combaids {Span
Diagnostics}], followed by an ELISA [Labsystems]).
All participants in groups 1 and 3 except 1 participant in
group 3 were sputum-smear positive for acid-fast bacilli and
were receiving standard anti-TB regimens. Mycobacterial cul-
tures were performed only for 16 patients in group 3; Myco-
bacterium tuberculosis was isolated for 15 patients. One patient
in group 3 had extrapulmonary TB with pleural effusion. None
of the patients in group 1 complained of diarrhea or vomiting
for 3 days before the start of the study. None of the HIV-
seropositive patients in groups 2 and 3 were receiving antiret-
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Table 1. Characteristics of patients in the different study groups.
Group
No. of
patients
Mean value  SD
Age, years Body weight, kg
Patients with TB 23 41.2  6.8 40.1  7.1
HIV-infected patients with diarrhea 40 33.7  6.3 42.8  6.0
HIV-infected patients with TB 26 36.7  7.0 43.3  6.6
NOTE. TB, tuberculosis.
roviral treatment, but they were receiving medications for other
opportunistic infections, in addition to multivitamins. None of
these patients were receiving any stool binders, such as pectin
or kaolin, or were receiving any medications known to interfere
with the absorption of isoniazid or rifampicin. The healthy
volunteers were staff and students of the Tuberculosis Research
Centre (Chennai). The study was conducted after obtaining
approval from the Ethics Committee of the health care center,
and informed written consent was obtained from each
participant.
Baseline demographic, clinical, and laboratory data were ob-
tained from all eligible study patients. Rifampin and isoniazid
were withheld for a period of 48–72 h before the start of the
study. All participants received rifampin (450 mg) and isoniazid
(300 mg) orally under supervision. Two hours later, a uniform
oral dose of D-xylose (5 g) in water was administered. Urine
excreted up to 8 h after drugs were administered was obtained;
the volume was measured, and aliquots were stored at 20C.
Ascorbic acid was added to urine aliquots to prevent oxidation
of rifampin. The D-xylose absorption test was performed for
10 healthy volunteers (mean age, 38.0 years; mean body weight,
65.4 kg).
The concentration of rifampin and its primary metabolite,
desacetyl rifampin (DRMP), were measured by a high-perfor-
mance liquid chromatography method developed in our lab-
oratory [11]. The concentration of isoniazid and its metabolite,
acetyl isoniazid (AcINH) [12], and that of D-xylose were mea-
sured by spectrophotometric methods [13]. The values were
expressed as percentage of dose of rifampin (rifampin and
DRMP), isoniazid (isoniazid and AcINH), and D-xylose ex-
creted in urine. All estimations were undertaken after coding
the samples.
Analysis of data was performed using the SPSS software pack-
age, version 10.5 (SPSS). The significance of differences in mean
percentage of dose between the 2 study groups was evaluated
using an unpaired Student’s t test, and analysis of differences
between 12 groups was performed using analysis of variance.
Significance was defined at the 5% level. Pairwise correlation
between excretion of D-xylose, rifampin, and isoniazid and
CD4 lymphocyte counts was calculated using Pearson’s cor-
relation method.
Results. The baseline demographic characteristics of all of
the patients are shown in table 1. CD4 lymphocyte counts were
available for only 17 patients each in groups 2 and 3, and the
mean values were 123 and 61 cells/mm3, respectively. The mean
CD4 lymphocyte count was significantly lower in group 3 than
in group 2. Examination of stool specimens revealed Crypto-
sporidium parvum in almost all of the cases in groups 2 and
3. Many patients had mixed infection, including infection with
Candida species, Ascariasis species, Hymenolepis nana, and En-
tamoeba histolytica. None of the patients had tubercle bacilli
detected on stool smear. The renal function of the patients in
all 4 study groups was normal.
The mean percentage of dose of D-xylose excreted in urine
for patients with TB was 30.2, which was not significantly dif-
ferent from that for the healthy volunteers (30.0). Therefore,
for additional comparison with respect to drug levels, group 1
was considered to be the control group with which groups 2
and 3 were compared. The mean percentages of doses of D-
xylose for groups 2 and 3 were 17.0 and 20.9, respectively, both
of which were significantly lower than that for group 1 (P !
) (figure 1A)..001
A significant reduction in the mean percentage of dose of
rifampin and DRMP excreted was observed in groups 2 and
3, compared with group 1 (7.4, 6.6, and 10.1, respectively;
). Excretion of rifampin and DRMP was reduced by 27%P ! .01
and 34% in groups 2 and 3, respectively (figure 1B).
The mean percentages of doses of isoniazid and AcINH ex-
creted in groups 1, 2, and 3 were 49.6, 37.9, and 38.3, respectively.
A significant decrease in the excretion of isoniazid and AcINH
was observed in groups 2 and 3, compared with group 1 (P !
): the mean reduction in the excretion of the drug in groups.05
2 and 3 was 24% and 23%, respectively (figure 1C). No significant
differences in the urinary excretion of D-xylose, rifampin, and
isoniazid were observed between groups 2 and 3.
A significant positive correlation existed between percentage
of dose of D-xylose and that of rifampin and isoniazid in urine
( and 0.49, respectively; ). However, the CD4rp 0.55 P ! .001
lymphocyte counts correlated significantly only with percentage
of dose of rifampin ( ; ). Also, the correlationrp 0.38 P ! .01
between percentage of dose excreted of rifampin and of iso-
niazid was significant ( , ).rp 0.34 P ! .01
Discussion. Tuberculosis is the most common opportun-
istic infection in HIV-infected patients in India. Despite initial
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Figure 1. The mean percentage of dose of D-xylose (A), rifampin
(RMP) and desacetyl RMP (DRMP) (B), and isoniazid (INH) and acetyl INH
(AcINH) (C) excreted in urine up to 8 h after dosing in patients with
tuberculosis (TB), HIV infection and diarrhea (HIV), and HIV and TB (HIVTB).
Vertical bars, SD. * .P ! .05
observations that standard multiple-drug regimens are as ef-
fective in HIV-infected patients as in HIV-uninfected patients,
there have been disconcerting reports of low levels of anti-TB
drugs in patients with HIV infection and TB [2–6, 8].
Most patients with TB but without other illnesses absorb
antimycobacterial drugs reliably [14]. This finding is in agree-
ment with ours: the excretion of D-xylose was similar in pa-
tients with TB and healthy volunteers. However, patients with
gastrointestinal disorders and AIDS have less predictable ab-
sorption of antimycobacterial drugs. Our study provides a qual-
itative estimate of the effect of HIV infection on the absorption
of the 2 key anti-TB drugs (rifampin and isoniazid) based on
the urinary excretion of the drugs and their metabolites.
It has been reported that urine kinetics are as good a means
as blood kinetics to obtain information on the bioavailability
of anti-TB drugs [15–17]. Because the procedure is noninvasive
and relatively easy to perform, obtaining estimates of urine
excretion of rifampin and isoniazid and their metabolites was
undertaken in this study. Creatinine levels were determined in
all urine samples to ensure that the urine collections were com-
plete (i.e., the entire volume of urine excreted by the patient
during the study period was collected).
The data obtained in this study clearly demonstrate that the
rate of urinary excretion of both rifampin and isoniazid was
significantly lower in both groups of HIV-infected patients than
in the TB group. These findings are supported by a significant
decrease in D-xylose absorption as well.
There does not appear to be a single patient characteristic
or diagnostic test that reliably predicts the propensity for drug
malabsorption in an individual patient, although a low CD4
count and gastrointestinal disturbances appear to increase the
likelihood of significant malabsorption [8]. This aspect has been
confirmed by our data, because we found a significant corre-
lation between CD4 lymphocyte count and urinary level of
rifampin. The results of this study further suggest that D-xylose
absorption testing of urine samples, which is simple to perform,
can be used to screen HIV-infected patients who may not be
absorbing rifampin and isoniazid adequately. This observation
is in agreement with the report by Sahai et al. [8]. Among the
26 HIV-infected patients with TB, 11 had chronic diarrhea.
However, diarrhea did not seem to influence the absorption of
rifampin and isoniazid, as evidenced by the fact that HIV-
infected patients without diarrhoea did not differ significantly
from patients with diarrhea with regard to urinary levels of D-
xylose, rifampin, and isoniazid.
Our preliminary findings are, to our knowledge, the first on
the existence of malabsorption of anti-TB drugs in HIV-
infected patients from the Indian subcontinent. We have doc-
umented the presence of a significant degree of malabsorption
among patients with advanced HIV infection, with and without
diarrhea. This could have implications for treatment of TB in
HIV-infected patients. A larger prospective study would be re-
quired to correlate low drug levels and poor response to anti-
TB treatment. The population in this study included both pa-
tients with new and patients with previously treated TB and
were generally in an advanced stage of HIV disease. Clinicians
must maintain a high index of suspicion for drug malabsorp-
tion in patients with AIDS. Some authors recommend thera-
peutic drug monitoring of anti-TB drugs in patients with AIDS
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[18]. This proposal has significant cost and health policy im-
plications. Alternately, estimation of rifampin and isoniazid lev-
els in urine, as was done in this study, could provide important
information on the absorption of these drugs. Pharmacokinetic
studies are in progress to confirm the results obtained in this
study.
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